phase ib trial of ianalumab plus ibrutinib for cll
Published 2 years ago • 438 plays • Length 4:08Download video MP4
Download video MP3
Similar videos
-
4:43
phase ib trial of ianalumab plus ibrutinib for cll
-
3:51
phase ib trial of ianalumab and ibrutinib in cll
-
1:47
ianalumab add-on therapy in cll patients receiving ibrutinib
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
2:57
the cll12 trial of ibrutinib in early stage cll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
4:02
living with chronic lymphocytic leukaemia (cll)
-
8:42
my must-have products for sjogren's syndrome
-
2:10
overview of cll12 trial of ibrutinib aiming to delay chemoimmunotherapy
-
1:28
overview of resonate-2 clinical trial of ibrutinib in cll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
1:25
preliminary results from a phase ib trial of as-1763, a novel non-covalent btki, in cll/mcl
-
2:51
key btk inhibitor trials for the initial treatment of cll
-
0:49
overview of the cll2-big trial of ibrutinib and obinutuzumab
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
1:21
evolving management of relapsed cll: uk cll forum analysis of ibrutinib at first relapse
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
1:07
ibrutinib treatment for cll yields different pfs in population-based setting